Shanghai, China

Xiaofang Deng

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mabwell (Shanghai) Bioscience Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Xiaofang Deng in Antibody Development

Introduction

Xiaofang Deng is a prominent inventor based in Shanghai, China. She has made significant contributions to the field of bioscience, particularly in the development of antibodies. Her innovative work has led to the filing of a patent that showcases her expertise and dedication to advancing medical science.

Latest Patents

Xiaofang Deng holds a patent titled "Antibody Against Nectin-4 and Application Thereof." This patent represents her groundbreaking research and development efforts in creating therapeutic solutions that target specific proteins involved in various diseases. She has 1 patent to her name, reflecting her commitment to innovation in the bioscience sector.

Career Highlights

Deng is currently employed at Mabwell (Shanghai) Bioscience Co., Ltd., where she continues to push the boundaries of scientific research. Her role at Mabwell allows her to collaborate with other talented professionals in the field, contributing to the company's mission of developing advanced biopharmaceuticals.

Collaborations

Xiaofang Deng has worked alongside notable colleagues, including Hongyuan Ren and Jian Zhu. These collaborations have fostered a dynamic environment for innovation and have enhanced the quality of research conducted at Mabwell.

Conclusion

Xiaofang Deng's contributions to antibody development exemplify her dedication to advancing medical science. Her innovative spirit and collaborative efforts position her as a key figure in the bioscience industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…